Solu Therapeutics appoints new COO

Boston, USA-based biotech Solu Therapeutics today announced the appointment of Enda Moran as chief operating officer (COO).

Solu is developing therapies to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. It announced the successful completion of a $41 million Series A financing in April this year, which included US pharma major Eli Lilly (NYSE: LLY) as a new investor.

As COO, Dr Moran will lead core operational functions at Solu including chemistry manufacturing and controls (CMC), quality, program management, IT, and facilities management. He will also play a key role in building the infrastructure needed to support Solu's CyTAC (cytotoxicity targeting chimera) and TicTAC (therapeutic index control targeting chimera) platforms as the company progresses toward multiple clinical and regulatory milestones.